Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC50 of 0.35 μM. It is also a competitive inhibitor of Cdk2-cyclin E with respect to ATP, with Ki and IC50 values of 13.3 and 20 μM, respectively.CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 32.00 | |
5 mg | In stock | $ 72.00 | |
10 mg | In stock | $ 138.00 | |
25 mg | In stock | $ 233.00 | |
50 mg | In stock | $ 346.00 | |
100 mg | In stock | $ 513.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 81.00 |
Description | CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC50 of 0.35 μM. It is also a competitive inhibitor of Cdk2-cyclin E with respect to ATP, with Ki and IC50 values of 13.3 and 20 μM, respectively.CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity. |
Targets&IC50 | CDK9-CyclinT1:0.35 μM |
In vitro | The most potent inhibitor,CAN508, reduced the frequency of S-phase cells of the cancer cell line HT-29 in antiproliferation assays.?Further observed cellular effects included decreased phosphorylation of the retinoblastoma protein and the C-terminal domain of RNA polymerase II, inhibition of mRNA synthesis, and induction of the tumor suppressor protein p53, all of which are consistent with inhibition of CDK9. |
Molecular Weight | 218.22 |
Formula | C9H10N6O |
CAS No. | 140651-18-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (1145.63 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CAN508 140651-18-9 Cell Cycle/Checkpoint CDK inhibit CAN-508 ATP-competitive Cyclin dependent kinase esophageal cells Inhibitor adenocarcinoma HT-29 CAN 508 inhibitor